# A Bioequivalence Study of Hetrombopag in Healthy Subjects

> **NCT05088655** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Sever Aplastic Anaemia

## Interventions

- **DRUG:** Hetrombopag Olamine Tablet

## Key facts

- **NCT ID:** NCT05088655
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-25
- **Primary completion:** 2022-07-25
- **Final completion:** 2023-11-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088655, "A Bioequivalence Study of Hetrombopag in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05088655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*